The outlook of companies tied to Sildenafil's past presents a challenging investment picture . While the initial surge generated substantial profits , generic competition have significantly eroded revenue. Investing in related pharmaceutical companies now requires a discerning assessment of intellectual property protection , evolving patient shifts